Kevin Joseph Fitzgerald - Net Worth and Insider Trading
Kevin Joseph Fitzgerald Net Worth
The estimated net worth of Kevin Joseph Fitzgerald is at least $3 Million dollars as of 2024-12-27. Kevin Joseph Fitzgerald is the CSO & EVP, Head of Research of Alnylam Pharmaceuticals Inc and owns about 13,418 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $3 Million. Details can be seen in Kevin Joseph Fitzgerald's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kevin Joseph Fitzgerald has not made any transactions after 2024-11-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Kevin Joseph Fitzgerald
Kevin Joseph Fitzgerald Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kevin Joseph Fitzgerald owns 1 companies in total, including Ovid Therapeutics Inc (OVID) .
Click here to see the complete history of Kevin Joseph Fitzgerald’s form 4 insider trades.
Insider Ownership Summary of Kevin Joseph Fitzgerald
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| OVID | Ovid Therapeutics Inc | 2021-10-06 | director |
Kevin Joseph Fitzgerald Latest Holdings Summary
Kevin Joseph Fitzgerald currently owns a total of 1 stock. Kevin Joseph Fitzgerald owns 13,418 shares of Alnylam Pharmaceuticals Inc (ALNY) as of November 27, 2024, with a value of $3 Million.
Latest Holdings of Kevin Joseph Fitzgerald
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | 2024-11-27 | 13,418 | 238.19 | 3,196,033 |
Holding Weightings of Kevin Joseph Fitzgerald
Kevin Joseph Fitzgerald Form 4 Trading Tracker
According to the SEC Form 4 filings, Kevin Joseph Fitzgerald has made a total of 3 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 3,000 shares on November 27, 2024, which brought Kevin Joseph Fitzgerald around $754,950.
Insider Trading History of Kevin Joseph Fitzgerald
- 1
Kevin Joseph Fitzgerald Trading Performance
Kevin Joseph Fitzgerald Ownership Network
Kevin Joseph Fitzgerald Owned Company Details
What does Ovid Therapeutics Inc do?
Who are the key executives at Ovid Therapeutics Inc?
Kevin Joseph Fitzgerald is the director of Ovid Therapeutics Inc. Other key executives at Ovid Therapeutics Inc include director & 10 percent owner & CEO Jeremy M Levin , Chief Commercial Officer Jason Tardio , and 10 percent owner Takeda Pharmaceuticals U.s.a., Inc. .
Ovid Therapeutics Inc (OVID) Insider Trades Summary
Over the past 18 months, Kevin Joseph Fitzgerald made no insider transaction in Ovid Therapeutics Inc (OVID). Other recent insider transactions involving Ovid Therapeutics Inc (OVID) include a net purchase of 18,248 shares made by Jeremy M Levin ,
In summary, during the past 3 months, insiders sold 0 shares of Ovid Therapeutics Inc (OVID) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ovid Therapeutics Inc (OVID) were sold and 18,248 shares were bought by its insiders, resulting in a net purchase of 18,248 shares.
Ovid Therapeutics Inc (OVID)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ovid Therapeutics Inc Insider Transactions
Kevin Joseph Fitzgerald Mailing Address
Above is the net worth, insider trading, and ownership report for Kevin Joseph Fitzgerald. You might contact Kevin Joseph Fitzgerald via mailing address: C/o Ovid Therapeutics Inc., 1460 Broadway, Suite 15044, New York Ny 10036.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
